Business Context and Reporting Period
This Form 8-K Current Report was filed by Aquestive Therapeutics, Inc. on June 6, 2024, covering events occurring on June 3, 2024. The filing addresses Item 5.02 regarding the appointment of a new executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and compensation adjustments rather than financial performance.
Material Changes
The primary material change reported is the promotion of Cassie Jung to the position of Chief Operating Officer, effective June 3, 2024. Ms. Jung, who joined the company in 2004, previously served as Vice President of Operations. In connection with this promotion, her annual base salary was increased to $349,800.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. It notes that Ms. Jung's target award opportunity under the annual incentive program may not be less than 40% of her base salary and that she is eligible for other incentive and benefit plans. The employment agreement will be filed in the next Form 10-Q.
Investor Verification Checklist
- Verify the effective date of Cassie Jung's promotion to Chief Operating Officer (June 3, 2024).
- Confirm the new annual base salary of $349,800 and the minimum 40% target award opportunity.
- Review the upcoming Form 10-Q for the full text of the employment agreement.
- Check for any related party transactions or family relationships, which the filing explicitly states do not exist.